LAG3 and Miyoshi myopathy: Importantly, among the clinical grade checkpoint inhibitors and immune agonists evaluated in these studies, anti-LAG3 treatment significantly enhanced the proliferation of MM-specific effector cells and their functional activities in response to MM.